spacer
home > ict > autumn 2017 > restricting regulations
PUBLICATIONS
International Clinical Trials

Restricting Regulations

Contemporary medicine has come a long way since the days of snake oil salesmen. Today, patients can be assured that prescribed medicine has been vetted for safety and efficacy through a long and arduous process, guided by governmental regulatory agencies. The central pillar of this rigorous procedure for current drug approval is the human clinical trial, the success of which has resulted in a proliferation of studies worldwide. Since the international committee of medical journal editors established trial registration requirements in 2005, enrolment has increased fivefold (1). In the US alone, clinical trial registration has increased tenfold during this same time period, but, against this backdrop, the EU recorded a concerning 25% decrease in clinical trial applications (CTA) from 2007 to 2011 (2).

Global Trials

One of the issues affecting the number of EU studies is a growing trend towards globalisation, with a recent rise in those conducted in developing countries. For example, the number of countries serving as study locations outside the US has more than doubled in the past 10 years, and the proportion of trials undertaken there and in Western Europe has reduced significantly (3,4).

Several factors drive this globalisation trend – one of them being the spiralling drug development costs. A 2013 study by the Tufts Center for the Study of Drug Development estimates the average expense to develop and gain market approval for a new therapeutic is $2.6 billion – up 145% from a similar investigation conducted in 2003 – with time costs accounting for half of that amount. The time and investment required to conduct trials is the largest contributor to these increases, and, given that the success rate for medications moving through clinical trials to FDA approval is a mere 10%, the pharmaceutical industry is struggling to sustain profitability (5).

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Craig Morgan is Head of Marketing at goBalto, a life sciences software as a service technology organisation. He works with sponsors, CROs, medical device manufacturers and sites to reduce cycle times and improve collaboration and oversight in clinical trials. Craig is a technology and life sciences management professional, with over 15 years’ experience in informatics and bioinformatics applications to drug discovery. He holds degrees in analytical chemistry, information systems and business administration and is a certified
spacer
Craig Morgan
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

BioIVT Introduces New Quality Management System to Maintain Highest Quality Biospecimens and Drug Development Research Services

BioIVT, a leading provider of research models and services for drug and diagnostic development, today announced that it is introducing a new internal cloud-based Quality Management System (QMS), Master Control. This new standardized, ISO compliant QMS will help BioIVT manage documentation, auditing, supplier and customer accounts, and risk across all locations. It will consolidate and replace a variety of computer- and paper-based document control systems located at existing and newly-acquired BioIVT sites in the US, Europe and Asia.
More info >>

White Papers

Time lapse photography to demonstrate the potential antimicrobial abilities of Dycem contamination control flooring

Dycem

A defined volume of bioluminescent reporter bacteria was deposited onto 20 mm x 20 mm coupons of Dycem flooring, vinyl tile and ITW Alma tacky mat. Through monitoring of bacterial bioluminescence, metabolic inhibition was observed on all three surfaces however the effect occurred more rapidly on Dycem flooring than on vinyl or ITW Alma. Recovery counts after three hours of exposure to the floor surfaces showed between a 65% and 100% decrease in the number of viable organisms recovered from Dycem flooring compared to controls. On vinyl and ITW Alma flooring, there were slight increases in the number of viable survivors recovered compared to controls. Dycem flooring inhibited the metabolic activity and reduced the number of viable survivors recovered of Salmonella enterica Serovar Typhimurium DT104 pGLITE. It remains unclear as to whether this effect is attributable to the impregnated biocide or rapid drying of the inoculum on this surface.
More info >>

 
Industry Events

PDA Parenteral Packaging 2019

19-20 March 2019, Hilton Molino Stucky, Venice, Italy

PDA Europe’s Conference has become a must-attend event for all professionals in the Parenteral Packaging arena. Join us in Venice in March 2019 to continue and further deepen scientific advancements and our ongoing professional discourse of latest on primary packaging technologies and business trends. This conference and the accompanying exhibition address quality of components and cont­ainers, container closure development and integrity testing as well as aspects of processing, product distribution and storage.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement